Comparative Efficacy and Safety of Inhaled Fluticasone Propionate and Beclomethasone Dipropionate in the Treatment of Asthma: A Review

Larsen GL . Asthma in children. N Engl J Med 1992;326(23):1540–1545.

National Institutes of Health. National Asthma Education Program. Guidelines for the Diagnosis and Management of Asthma. Bethesda MD: National Heart, Lung and Blood Institute; 1991.

National Institutes of Health. International Consensus Report on Diagnosis and Treatment of Asthma. Washington DC: U.S. Department of Health and Human Services, 1992.

Expert Panel on the Management of Asthma II. Guidelines for the Diagnosis and Management of Asthma: Highlights of the Expert Panel Report II. Bethesda MD: National Heart, Lung, and Blood Institute; 1997.

Kaliner MA . Evolution of asthma treatments. Ann Allergy 1993;71(3):300–305.

Barnes PJ . Preventative therapy in adults with asthma. Respir Med 1991;85(5):355–357.

Barnes PJ , Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Report of a workshop held in Eze, France, October 1992. Am Rev Respir Dis 1993;148(4 Pt 2):S1–S26.

Barnes PJ . Anti-inflammatory therapy for asthma. Annu Rev Med. 1993;44:229–242.

Allen DB , Mullen M , Mullen B. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J Allergy Clin Immunol 1994;93(6):967–976.

Schimmer BP , Parker KL . Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Hardman J , Limbird L , editors. Goodman & Gilman's The pharmacological basis of therapeutics, 9th edition. New York: McGraw-Hill; 1995:1459–1485.

Redman BG , Pasdur R , Zingas AP , Loredo R. Prospective evaluation of adrenal insufficiency in patients with metastasis. Cancer. 1987;60(1):103–107.

Harding SM . The human pharmacology of inhaled fluticasone propionate. Respir Med 1990;84(Suppl A):25–29.

Glaxo Wellcome. Flovent® (fluticasone propionate) inhalation aerosol product information. Research Triangle Park NC: Glaxo Wellcome, 1996.

Holliday SM , Faulds D , Sorkin EM . Inhaled fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma. Drugs 1994;47(2):318–331.

Food and Drug Administration. FDA Pulmonary-Allergy Drugs Advisory Committee meeting of September 25, 1995. Transcript. U.S. FDA file #14864.

Levy DS . Flovent (abstract). J Allergy Clin Immunol 1997;99:861–862.

Grahnen A , Eckernas S-A , Brundin RM , Ling-Andersson A. An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. Br J Clin Pharmacol 1994;38(6):521–525.

Grove A , Allam C , McFarlane LC , McPhate G , Jackson CM , Lipworth BJ . A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects. Br J Clin Pharmacol 1994;38(6):527–532.

Dogterom P , Oosterhuis B , Ebels JT , Jonkman JHG . Inhaled fluticasone propionate induces greater cortisol suppression compared to budesonide. A dose-response study using pressurized metered dose inhalers (PMDI's). Annual Congress of the European Respiratory Society. Barcelona, Spain, September 16-20, 1995.

LeBlanc P , Mink S , Keistinen T , Saarelainen PA , Ringdal N , Payne SL . A comparison of fluticasone propionate 200 micrograms/day with beclomethasone dipropionate 400 micrograms/day in adult asthma [published erratum appears in Allergy 1994;49(10):908]. Allergy 1994;49(5):380–385.

Lundback B , Alexander M , Day J , Hebert J , Holzer R , Van Uffelen R , Kesten S , Jones AL . Evaluation of fluticasone propionate (500 µg day^-1) administered either as a dry powder via a Diskhaler® inhaler or pressurized inhaler and compared with beclomethasone dipropionate (1000 µg day^-1) administered by pressurized inhaler. Respir Med 1993;87(8):609–620.

Gustafsson P , Tsanakas J , Gold M , Primhak R , Radford M , Gillies E. Comparison of the efficacy and safety of inhaled fluticasone propionate 200 µg/day with inhaled beclomethasone dipropionate 400 µg/day in mild and moderate asthma. Arch Dis Child 1993;69(2):206–221.

Dahl R , Lundback B , Malo JL , Mazza JA , Nieminen MM , Saarelainen P , Barnacle H. A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. International Study Group. Chest 1993;104(5):1352–1358.

Clark DJ , Grove A , Cargill RI , Lipworth BJ . Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 1996;51(3):262–266.

Boe J , Bakke P , Rødølen T , Skovlund E , Gulsvik A. High-dose inhaled steroids in asthmatics: moderate efficacy gain and suppression of the hypothalamic-pituitary-adrenal (HPA) axis. Research Council of the Norwegian Thoracic Society. Eur Respir J 1994;7(12):2179–2184.

Fabbri L , Burge PS , Croonenborgh L , Warlies F , Weeke B , Ciaccia A , Parker C. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. Thorax 1993;48(8):817–823.

Barnes NC , Marone G , Di Maria GU , Visser S , Utama I , Payne SL . A comparison of fluticasone propionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma. International Study Group. Eur Respir J 1993;6(6):877–885.

Ayres JG , Bateman ED , Lundback B , Harris TAJ . High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. Eur Respir J 1995;8(4):579–586.

Bakke P , Boe J , Rødølen T , Skovlund E , Gulsvik A. Fluticasone propionate 2.0 mg daily suppresses the hypothalamo-pituitary-adrenal axis in moderate to severe asthmatics (abstract). Am J Respir Crit Care Med 1994;149:A215.